




The First Enantioselective Synthesis of Optically Pure (*R*)- and (*S*)-5,5''-Dihydroxy-4',4''',7,7''-tetramethoxy -8,8''-biflavone and the Reconfirmation of Their Absolute Configuration

Guo-Qiang Lin* and Min Zhong

Shanghai Institute of Organic Chemistry, Chinese Academy of
Sciences, 354 Fenglin Lu, Shanghai, 200032, China

Abstract The first enantioselective synthesis of the optically pure (*R*)- and (*S*)-5,5''-dihydroxy-4',4''',7,7''-tetramethoxy -8,8''-biflavone is described. The key steps involve the intramolecular oxidative coupling of the cyanocuprate intermediate and Friedel-Crafts rearrangement. Their absolute configuration was reconfirmed by CD spectra. © 1997, Elsevier Science Ltd. All rights reserved.

In 1968, Ilyas and his coworkers¹ isolated (-)-5,5''-dihydroxy-4',4''',7,7''-tetramethoxy -8,8''-biflavone (**1**) from *Araucaria cunninghamii* and *A. cooki* as the first optically pure biflavone. Since then, 13 other optically active biflavones of three groups, *i.e.*, cupressflavones, amentoflavones, and agathisflavones, have been isolated from a variety of plants. There is now ample evidence of the pharmacological effects of biflavones including inhibition of cyclic AMP phosphodiesterase^{2a} and inhibition of lens aldose reductase^{2b}, *etc.* In most cases, the biflavones proved to be more active than the monomeric species.




1

The chirality of those biflavones is due to the atropisomerism of the biflavone moiety. Although the racemic 5,5''-dihydroxy-4',4''',7,7''-tetramethoxy -8,8''-biflavone or its derivatives have been synthesized by various methods³, and the absolute configuration of the naturally occurring 5,5''-dihydroxy-4',4''',7,7''-tetramethoxy -8,8''-biflavone was deduced as a*R* by Harada *et al.*⁴ and later on confirmed by us^{3g}, to our knowledge, there was no report of enantioselective synthesis of the optically active (*R*)- or (*S*)-**1**. As a

continuation of our efforts in this area, we report here the first enantioselective synthesis of the optically pure (*R*)- and (*S*)-1, in which the asymmetric intramolecular oxidative coupling of the cyanocuprate intermediate of **6** developed by Lipshutz's group⁵ and the Friedel-Crafts rearrangement of **13** were employed as the key steps. We have also reconfirmed their absolute configuration by CD spectra.

Scheme 1




Reagents and conditions: a. TBDMSCl, imidazole, DMF, r.t., 24 h, 84%; b. 2-iodo-3,5-dimethoxyphenol, DEAD, *n*-Bu₃P, THF, r.t., 24 h, 68%; c. *n*-Bu₄NF, THF, 2 h, 90%; d. 2-iodo-3,5-dimethoxyphenol, DEAD, *n*-Bu₃P, THF, r.t., 42 h, 42%; e. *n*-BuLi, THF, -78°C, 1 h; CuCN-TMEDA(1:3), -78°C → -40°C, 1 h; dry O₂, -78°C, 4 h, 75%; f. 10% Pd/C, H₂, EtOAc, 12 h, 100%; g. TsCl, py., 0 °C, 8 h, 92%; h. NaI, acetone, reflux, 3 h, 85%; i. activated Zn powder, EtOH, reflux, 1 h, 80%; j. (*S*)-α-methoxy-α-(trifluoromethyl)-phenylacetyl chloride, 4-DMAP, Et₃N, CH₂Cl₂, r.t., 24 h, 90%.

As shown in scheme 1, 1,4-di-*O*-benzyl-D-threitol (**2**)⁶ was converted to its monosilyl ether (**3**). Mitsunobu reaction⁷ of **3** with 2-iodo-3,5-dimethoxyphenol⁸, with the configuration transformation from *S* to *R* at the reaction center, gave **4** in 68% yield. Cleavage of the silyl ether of **4** with *n*-Bu₄NF in THF gave **5** in 90% yield, which was followed by treatment with 2-iodo-3,5-dimethoxyphenol again to give the (2*R*,3*R*)-tetraether (**6**)⁹ in 42% yield. The low yield of the second Mitsunobu reaction was possibly caused by the steric hindrance at the coupling center. The attempt of the condensation of two molecules of 2-iodo-3,5-dimethoxyphenol to **2** in one step failed. Treatment of **6** with *n*-BuLi followed by addition of CuCN-TMEDA (1:3) led to formation *in situ* of a higher order cyanocuprate intermediate⁵, which transformed to **7**¹⁰ upon exposure to dry oxygen at -78°C in 75% yield. In order to obtain the biphenol (**11**) from **7**, a four-step process was designed to cleave the chiral auxiliary. Catalytic hydrogenation of **7** gave the threitol (**8**) in quantitative

yield. The threitol (**8**) was converted to the ditosylate (**9**) in 92% yield, which upon treatment with NaI gave the diiodide (**10**) in 85% yield. Reduction of **10** by activated zinc powder in ethanol provided the biphenol (**11**) in 80%. The diastereomeric excess of **11** was determined to be 81% by the examination of the ^1H NMR spectra of its corresponding (*S*)-Mosher's ester (**12**). The optically pure **11**¹¹ was obtained by recrystallization from ethyl acetate and hexane.

Subsequently, our efforts were made to complete the synthesis of the optically pure **1** (Scheme 2).

Scheme 2



Reagents and conditions: a. $(\text{CH}_3\text{CO})_2\text{O}$, py., 2 h, 93%; b. TiCl_4 , benzene, reflux, 1 h, 94%; c. *p*-anisaldehyde, KOH, cat. TEBACl, $\text{EtOH-H}_2\text{O}$ (3:2), r.t., 48 h, 80%; d. I_2 , DMSO, 150°C , 30 min., 60%; e. BCl_3 , CH_2Cl_2 , 0°C , 1 h, 84%.

The diacetate (**13**), generated from **11** by treatment with acetic anhydride in pyridine, underwent Friedel-Crafts rearrangement promoted by TiCl_4 as Lewis acid to afford **14**¹² in 94% yield. Treatment of **14** with *p*-anisaldehyde in presence of KOH and catalytic TEBACl as a phase-transfer reagent gave bichalcone (**15**) in 80% yield. Ring closure of **15** on heating with I_2 -DMSO^{3g} afforded **16** in 60% yield. Selective demethylation of **16** with BCl_3 ^{3d} in CH_2Cl_2 at 0°C gave (+)-**1**¹³ in 84% yield. The absolute configuration of the synthetic (+)-**1** $[\alpha]_D^{22} +76.6$ (c 0.11, EtOH)] was assigned as *aR* and was determined to be optically pure by comparison of the specific rotation value of (*R*)-**1** $[\alpha]_D^{18} +77$ (c 0.2, EtOH) for (*R*)-**1** with our previous report^{3g}. The CD curves of the synthetic (+)-**1** were in accordance with that of the naturally occurring **1**, which was deduced as *aR* by Harada *et al.*⁴. This result was also in agreement with Lipshutz's conclusion⁵ that the (2*R*,3*R*)-tetraether generally induced the formation of (*R*)-biaryl and the (2*S*,3*S*)-tetraether generally induced the formation of (*S*)-biaryl in the cyclization (**6**→**7**). Accordingly, the absolute configuration of the biaryls **7**, **8**, **9**, **10**, **11**, **12**, **13**, **14**,

15, 16 was all assigned as aR. In the same manner as that of preparation of (R)-1, the optically pure (S)-1 $[[\alpha]_D^{22} -77.3$ (c 0.13, EtOH)]¹³ was synthesized using 1,4-di-O-benzyl-L-threitol⁶ as the chiral auxiliary and the CD curves of the synthetic (S)-1 was contrary to that of the naturally occurring **1**.

In summary, we have accomplished the first enantioselective synthesis of the optically pure (R)- and (S)-5,5''-dihydroxy-4',4'''',7,7'''-tetramethoxy-8,8''-biflavone (**1**) and reconfirmed the absolute configuration of the naturally occurring **1** as aR by CD spectra.

References and Notes:

- Ilyas, M.; Usmani, J. N.; Bhatnagar, S. P.; Ilyas, M.; Rahman, W.; Pelter, A. *Tetrahedron Lett.*, **1968**, 5515.
- a. Beretz, A.; Joly, M.; Stoclet, J. C.; Anton, R. *Planta Med.*, **1979**, 36, 193. b. Felicio, J. D. A.; Gonzalez, E.; Braggio, M. M.; Costantino, L.; Albasini, A.; Lins, A. P. *Planta Med.*, **1995**, 61, 217.
- a. Nakazawa, K. *Chem. Pharm. Bull.*, **1962**, 10, 1032. b. Nurti, V. V. S.; Raman, P. V.; Soshardi, T. R. *Tetrahedron*, **1967**, 23, 397. c. Ahmad, S.; Razaq, S. *Tetrahedron Lett.*, **1971**, 4633. d. Ahmad, S.; Razaq, S. *Tetrahedron*, **1976**, 32, 503. e. Moriyama, S.; Okigawa, M.; Kawano, N. *J. Chem. Soc. Perkin I*, **1974**, 2132. f. Moriyama, S.; Okigawa, M.; Kawano, N. *Tetrahedron Lett.*, **1972**, 2105. g. Zhang, F.-J.; Lin, G.-Q.; Huang, Q.-C. *J. Org. Chem.*, **1995**, 60, 6427 and references cited therein; see also corrigendum: Zhang, F.-J.; Lin, G.-Q.; Huang, Q.-C. *J. Org. Chem.*, **1996**, 61, 5700.
- Harada, N.; Ono, H.; Uda, H.; Parveen, M.; Khan, N. U.; Achari, B.; Dutta, P. K. *J. Am. Chem. Soc.*, **1992**, 114, 7687.
- Lipshutz, B. H.; Kayser, F.; Liu, Z.-P. *Angew. Chem. Int. Ed. Engl.*, **1994**, 33, 1842 and references cited therein.
- Mash, E. A.; Nelson, K. A.; Densen, E. V.; Hemperly, S. B. *Org. Synth.*, coll. Vol. VIII; John Wiley and Sons. Inc.: New York, **1993**; p155.
- Hughes, D. L.; *Org. React.*; John Wiley and Sons. Inc.: New York, **1992**; p335.
- Bachki, A.; Foubelo, F.; Yus, M. *Tetrahedron Lett.*, **1994**, 50, 5139.
6. $[\alpha]_D^{22} -5.04$ (c 2.10, CHCl₃). FT-IR (film): 2938, 2841, 1583, 1454, 1413, 1365, 1342, 1223, 1201, 1162, 1112, 1018, 812, 738, 698 cm⁻¹. ¹H NMR (300MHz, CDCl₃) δ 7.27-7.32 (m, 10H), 6.39 (s, 2H), 6.15 (s, 2H), 4.82 (s, 2H), 4.53 (s, 4H), 4.09 (dd, 2H, $J = 2.75, 10.20$ Hz), 3.90 (dd, 2H, $J = 4.00, 9.84$ Hz), 3.86 (s, 6H), 3.66 (s, 6H) ppm. ¹³C NMR (75.5HMz, CDCl₃) δ 162.162, 159.230, 138.116, 128.368, 127.855, 127.667, 94.002, 92.900, 78.936, 73.749, 69.100, 68.899, 56.527, 55.560 ppm. MS m/z (EI, 70ev): 826, 699, 572, 514, 466, 354, 191, 155, 127, 105, 91(100). Calcd. for C₃₄H₃₆O₈l₂: C, 49.41; H, 4.39. Found: C, 49.33; H, 4.49.
- (aR)-7. $[\alpha]_D^{22} +34.7$ (c 0.59, CHCl₃). FT-IR (film): 2937, 2840, 1603, 1547, 1496, 1463, 1454, 1436, 1414, 1369, 1353, 1319, 1280, 1215, 1199, 1151, 1094, 1064, 1024, 1007, 935, 909, 874, 826, 799, 739, 699, 635, 603, 522, 530 cm⁻¹. ¹H NMR (300MHz, CDCl₃) δ 7.27-7.33 (m, 10H), 6.40 (d, 2H, $J = 2.39$ Hz), 6.34 (d, 2H, $J = 1.97$ Hz), 4.59, 4.58 (AB, 4H, $J_{AB} = 12.04$ Hz), 4.10 (dd, 2H, $J = 4.98, 6.67$ Hz), 3.73 (s, 12H), 3.72 (d, 2H, $J = 8.30$ Hz), 3.61 (tt, 2H, $J = 2.59, 8.22$ Hz) ppm. ¹³C NMR (75.5HMz, CDCl₃) δ 160.743, 160.056, 158.919, 138.315, 128.420, 127.708, 110.385, 99.121, 95.557, 85.136, 73.704, 70.682, 55.872, 55.365 ppm. MS m/z (EI, 70ev): 574, 573, 572 (19.5), 91(100). HRMS calcd. for C₃₄H₃₆O₈(M⁺): 572.2411, found 572.2460.
- (aR)-11. m.p 165-166°C (EtOAc/hexane). $[\alpha]_D^{21} +76.5$ (c 0.53, CHCl₃). FT-IR (KBr): 3410, 1612, 1584, 1523 cm⁻¹. ¹H NMR (300MHz, CDCl₃) δ 6.29 (d, 2H, $J = 2.35$ Hz), 6.20 (d, 2H, $J = 2.31$ Hz), 3.83 (s, 6H), 3.74 (s, 6H) ppm. MS m/z (EI, 70ev): 308, 307, 306 (100), 289, 275, 259, 245, 231, 215, 193, 77. Calcd. for C₁₆H₁₈O₆: C, 62.74; H, 5.92. Found: C, 62.35; H, 5.96. for (aS)-11. m.p 164-166°C (EtOAc/hexane). $[\alpha]_D^{20} -76.3$ (c 0.61, CHCl₃).
- (aR)-12. m.p 253-254°C (CHCl₃/EtOH). $[\alpha]_D^{20} -27.6$ (c 0.56, CHCl₃). CD (EtOH) λ_{ext} 298 nm ($\Delta\epsilon$ -3.29), 276 ($\Delta\epsilon$ +4.60), 241 ($\Delta\epsilon$ -1.34), 235 ($\Delta\epsilon$ -0.26), 229 ($\Delta\epsilon$ -2.63), 212 ($\Delta\epsilon$ +8.67). FT-IR (KBr): 2701, 1617, 1588, 1504 cm⁻¹. ¹H NMR (300MHz, CDCl₃) δ 14.02 (s, 2H), 6.08 (s, 2H), 3.95 (s, 6H), 3.83 (s, 6H), 2.63 (s, 6H) ppm. MS m/z (EI, 70ev): 392, 391, 390 (100), 375, 359, 333. Calcd. for C₂₀H₂₂O₈: C, 61.53; H, 5.68. Found: C, 61.07; H, 5.53. for (aS)-12. m.p 252-254°C (CHCl₃/EtOH). $[\alpha]_D^{19} +27.2$ (c 0.40, CHCl₃). CD (EtOH) λ_{ext} 297 nm ($\Delta\epsilon$ +3.38), 275 ($\Delta\epsilon$ -2.03), 240 ($\Delta\epsilon$ +3.78), 235 ($\Delta\epsilon$ +2.43), 230 ($\Delta\epsilon$ +3.78), 211 ($\Delta\epsilon$ -6.21).
- (aR)-1. m.p 152-153°C (MeOH). $[\alpha]_D^{22} +76.6$ (c 0.11, EtOH). CD (EtOH) λ_{ext} 355 nm ($\Delta\epsilon$ +17.0), 318 ($\Delta\epsilon$ -30.8), 258 ($\Delta\epsilon$ +14.0). FT-IR (KBr): 2934, 2833, 1615, 1609, 1588, 1511, 1486, 1427, 1373, 1264, 1241, 1206, 1179, 1123, 1029, 834, 572 cm⁻¹. ¹H NMR (300MHz, CDCl₃) δ 13.23 (s, 2H), 7.43 (dd, 4H, $J = 2.02, 7.01$ Hz), 6.87 (dd, 4H, $J = 1.95, 7.06$ Hz), 6.60 (s, 2H), 6.59 (s, 2H), 3.82 (s, 6H), 3.80 (s, 6H) ppm. ¹³C NMR (75.5HMz, CDCl₃) δ 183.030, 164.060, 163.504, 162.802, 154.817, 127.727, 123.455, 114.693, 105.427, 103.679, 99.692, 95.446, 56.347, 55.598 ppm. MS m/z (EI, 70ev): 597 (1.75), 596 (9.64), 595 (39.25), 594 (M⁺, 100), 433 (1.74), 297 (8.91), 135 (16.38), 77 (3.15). HRMS calcd. for C₃₄H₂₆O₁₀(M⁺): 594.1526, found 594.1553. for (aS)-1. m.p 153-154°C (MeOH). $[\alpha]_D^{22} -77.3$ (c 0.13, EtOH). CD (EtOH) λ_{ext} 359 nm ($\Delta\epsilon$ -23.2), 323 ($\Delta\epsilon$ +54.8), 264 ($\Delta\epsilon$ -15.2).

(Received in UK 11 November 1996; revised 13 December 1996; accepted 20 December 1996)